RT Journal Article
SR Electronic
T1 The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 1034
OP 1040
DO 10.15537/smj.2024.45.10.20240393
VO 45
IS 10
A1 Badawi, Rehab
A1 Fahmy Abou Taira, Naglaa Samy
A1 Hasby, Sara Essam
A1 Elkhalawany, Walaa
A1 Elrefaey, Waleed
A1 Ahmed Khalf, Nahla
A1 Ibrahim Okda, Hanaa
YR 2024
UL http://smj.org.sa/content/45/10/1034.abstract
AB Objectives: To examine the relation between liver fibrosis and chronic kidney disease (CKD) in metabolic-associated fatty liver disease (MAFLD) patients and its risk factors.Methods: The current study was carried out at Tanta University Hospital, Tanta, Egypt, from May 2021 to January 2023 and included 84 MAFLD patients with CKD and 80 MAFLD patients without CKD. All participants had been examined by abdominal ultrasonography and transient elastography with controlled attenuation parameter.Results: Chronic kidney disease patients exhibited a greater incidence of fibrosis compared to patients without CKD (75.6% vs. 24.4%). Logistic analysis demonstrated that the presence of multiple health conditions, such as MAFLD, diabetes mellitus, hypertension, and cardiovascular disease, were individually linked to CKD. Gender and body mass index were not independent factors related to CKD. Additionally, factors such as age, hyperuricemia, hypertriglyceridemia, hypercholesterolemia, hypoalbuminemia, hyperbilirubinemia, and viral hepatitis, apart from MAFLD comorbidities, were independently linked to CKD.Conclusion: Chronic kidney disease may represent a potential risk influence for liver fibrosis development in MAFLD patients.